PGF2α FP receptor contributes to brain damage following transient focal brain ischemia

Neurotoxicity Research

Volumn 15, Issue 1, 2009, Pages 62-70

  Saleem, Sofiyan ^a   Ahmad, Abdullah Shafique ^a   Maruyama, Takayuki ^b   Narumiya, Shuh ^c   Doré, Sylvain ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ONO PHARMACEUTICAL CO   (Japan)

^c KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

13,14 Dihydro 17 phenyl 18,19,20 trinor PGF2 isopropyl ester; Excitotoxicity; Latanoprost; Middle cerebral artery occlusion; Mouse; Neurodegeneration; Prostaglandin

Indexed keywords

LATANOPROST; N METHYL DEXTRO ASPARTIC ACID; PROSTAGLANDIN F RECEPTOR; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN RECEPTOR; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; N METHYLASPARTIC ACID; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN F; PROSTAGLANDIN F2ALPHA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN INFARCTION SIZE; C57BL 6 MOUSE; C57BL MOUSE; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CONTROLLED STUDY; EXCITOTOXICITY; GENE DELETION; HISTOPATHOLOGY; KNOCKOUT MOUSE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; TRANSIENT ISCHEMIC ATTACK; WILD TYPE; ANALYSIS OF VARIANCE; ANIMAL; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; DISEASE MODEL; GENETICS; METABOLISM; MOUSE MUTANT; NEUROLOGIC DISEASE;

MUS;

ANALYSIS OF VARIANCE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BRAIN INFARCTION; BRAIN INJURIES; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID AGONISTS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; N-METHYLASPARTATE; NERVOUS SYSTEM DISEASES; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, PROSTAGLANDIN; RECEPTORS, PROSTAGLANDIN E;

EID: 70349731769     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12640-009-9007-3     Document Type: Article

References (55)

1. Abdel-Halim MS, Hamberg M, Sjoquist B, Anggard E (1977) Identification of prostaglandin D2 as a major prostaglandin in homogenates of rat brain. Prostaglandins 14:633-643
2. Abramovitz M, Boie Y, Nguyen T, Rushmore TH, Bayne MA, Metters KM, Slipetz DM, Grygorczyk R (1994) Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem 269:2632-2636
3. Ahmad AS, Ahmad M, de Brum-Fernandes AJ, Doré S (2005) Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Res 1066:71-77
4. Ahmad AS, Saleem S, Ahmad M, Doré S (2006a) Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci 89:265-270
5. Ahmad AS, Zhuang H, Echeverria V, Doré S (2006b) Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J Neurotrauma 23:1895-1903
6. Ahmad M, Saleem S, Zhuang H, Ahmad AS, Echeverria V, Sapirstein A, Doré S (2006c) 1-HydroxyPGE1 reduces infarction volume in mouse transient cerebral ischemia. Eur J Neurosci 23:35-42
7. Ayata C, Ayata G, Hara H, Matthews RT, Beal MF, Ferrante RJ, Endres M, Kim A, Christie RH, Waeber C, Huang PL, Hyman BT, Moskowitz MA (1997) Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knock-out mice. J Neurosci 17:6908-6917
8. 2+ signals and neuronal death in brain ischemia. Stroke 38:674-676
9. 2α: Possible role in ischemic brain injury. Stroke 34:776-782
10. Breyer MD, Breyer RM (2001) G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 63:579-605
11. Chemtob S, Beharry K, Rex J, Varma DR, Aranda JV (1990a) Changes in cerebrovascular prostaglandins and thromboxane as a function of systemic blood pressure Cerebral blood flow autoregulation of the newborn. Circ Res 67:674-682
12. Chemtob S, Beharry K, Rex J, Varma DR, Aranda JV (1990b) Prostanoids determine the range of cerebral blood flow autoregulation of newborn piglets. Stroke 21:777-784
13. Choi DW (1992) Excitotoxic cell death. J Neurobiol 23:1261-1276
14. Coleman RA, Smith WL, Narumiya S (1994) International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46:205-229
15. Cuppoletti J, Malinowska DH, Tewari KP, Chakrabarti J, Ueno R (2007) Cellular and molecular effects of unoprostone as a BK channel activator. Biochim Biophys Acta 1768:1083-1092
16. Dietrich WD, Bramlett HM (2007) Hyperthermia and central nervous system injury. Prog Brain Res 162:201-217
17. Doré S, Otsuka T, Mito T, Sugo N, Hand T, Wu L, Hurn PD, Traystman RJ, Andreasson K (2003) Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol 54:155-162
18. 2 receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following β-amyloid exposure. Eur J Neurosci 22:2199-2206
19. Ellis EF, Wei EP, Kontos HA (1979) Vasodilation of cat cerebral arterioles by prostaglandins D2, E2, G2, and I2. Am J Physiol 237:H381-385
20. Endres M, Dirnagl U (2002) Ischemia and stroke. Adv Exp Med Biol 513:455-473
21. Hackam DG, Spence JD (2007) Combining multiple approaches for the secondary prevention of vascular events after stroke: A quantitative modeling study. Stroke 38:1881-1885
22. Hata AN, Breyer RM (2004) Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol Ther 103:147-166
23. Heaslip RJ, Sickels BD (1989) Evidence that prostaglandins can contract the rat aorta via a novel protein kinase C-dependent mechanism. J Pharmacol Exp Ther 250:44-51
24. Hoffman WE, Albrecht RF, Pelligrino D, Miletich DJ (1982) Effects of prostaglandins on the cerebral circulation in the coat. Prostaglandins 23:897-905
25. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, Ross ME (2001) Reduced susceptibility to ischemic brain injury and N-methyl-d-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA 98:1294-1299
26. 2α in the rat heart. Prostaglandins Other Lipid Mediat 80:110-119
27. 2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 12:225-229
28. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 122:217-224
29. 2α receptor. Prostaglandins 48:31-41
30. 2α - and hypoxia-induced contraction of rat intrapulmonary artery by p38 MAPK inhibition: A nitric oxide-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 289:L1039-L1048
31. 2α is required for NMDA receptor-mediated induction of c-fos mRNA in dentate gyrus neurons. J Neurosci 17:117-124
32. 2α receptors and receptor-coupled second messengers by cyclooxygenase inhibition in newborn pigs. J Pharmacol Exp Ther 272:15-19
33. Li X, Blizzard KK, Zeng Z, DeVries AC, Hurn PD, McCullough LD (2004) Chronic behavioral testing after focal ischemia in the mouse: Functional recovery and the effects of gender. Exp Neurol 187:94-104
34. 2α exacerbate hypoxic neuronal injury in neuron-enriched primary culture. Neurochem Res 33:490-499
35. 2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol 57:758-761
36. Lynch DR, Guttmann RP (2002) Excitotoxicity: Perspectives based on N-methyl-d-aspartate receptor subtypes. J Pharmacol Exp Ther 300:717-723
37. Manabe Y, Anrather J, Kawano T, Niwa K, Zhou P, Ross ME, Iadecola C (2004) Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Ann Neurol 55:668-675
38. 2α - induced luteolysis in rats. Am J Physiol Endocrinol Metab 283:E1308-E1315
39. 2α receptor mRNA in normal, hyperplastic and neoplastic skin. Carcinogenesis 21:1063-1066
40. 2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic Biol Med 40:376-387
41. + channels in cerebral microvessels of hypertensive and normotensive rats. Anesth Analg 102:571-576
42. Narumiya S, Sugimoto Y, Ushikubi F (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev 79:1193-1226
43. 2α. Prostaglandins 41:451-462 41
44. Ogawa S, Kitao Y, Hori O (2007) Ischemia-induced neuronal cell death and stress response. Antioxid Redox Signal 9:573-587
45. Perry CM, McGavin JK, Culy CR, Ibbotson T (2003) Latanoprost: An update of its use in glaucoma and ocular hypertension. Drugs Aging 20:597-630
46. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX (2003) Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 19:501-515
47. Shinohara Y (2006) Regional differences in incidence and management of stroke - is there any difference between Western and Japanese guidelines on antiplatelet therapy? Cerebrovasc Dis 21(Suppl 1):17-24
48. Stjernschantz J, Selénb G, Astin M, Resula B (2000) Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment. Prog Retin Eye Res 19:459-496
49. Sugimoto Y, Yamasaki A, Segi E, Tsuboi K, Aze Y, Nishimura T, Oida H, Yoshida N, Tanaka T, Katsuyama M, Hasumoto K, Murata T, Hirata M, Ushikubi F, Negishi M, Ichikawa A, Narumiya S (1997) Failure of parturition in mice lacking the prostaglandin F receptor. Science 277:681-683
50. Suzuki-Yamamoto T, Nishizawa M, Fukui M, Okuda-Ashitaka E, Nakajima T, Ito S, Watanabe K (1999) cDNA cloning, expression and characterization of human prostaglandin F synthase. FEBS Lett 462:335-340
51. 2α mediate inflammatory tachycardia. Nat Med 11:562-566
52. Toh H, Ichikawa A, Narumiya S (1995) Molecular evolution of receptors for eicosanoids. FEBS Lett 361:17-21
53. 2 in the hypothermia of rats caused by bacterial lipopolysaccharide. Proc Natl Acad Sci USA 79:6093-6097
54. Xu L, Sun J, Lu R, Ji Q, Xu JG (2005) Effect of glutamate on inflammatory responses of intestine and brain after focal cerebral ischemia. World J Gastroenterol 11:733-736
55. Xu W, Chou CL, Sun H, Fujino H, Chen QM, Regan JW (2007) FP prostanoid receptor-mediated induction of the expression of early growth response factor-1 by activation of a Ras/Raf/mitogen-activated protein kinase signaling cascade. Mol Pharmacol 73:111-118